About Abcellera Biologics Inc
Abcellera Biologics (NASDAQ:ABCL) is a biotech firm focused on discovering and developing next-generation antibody therapies to address challenging diseases. By leveraging a proprietary technology that combines artificial intelligence, deep genomics, and a massively parallel microfluidic lab-on-a-chip platform, Abcellera aims to revolutionize the speed and efficiency of therapeutic antibody discovery. The company's projects span a range of therapeutic areas, including infectious diseases, immuno-oncology, and neurodegeneration, with the objective to rapidly transform novel molecular insights into full-spectrum antibody therapies. Abcellera’s collaborative and partnership-driven approach enables it to work alongside some of the world’s leading biopharmaceutical companies, amplifying its impact across the healthcare ecosystem.
Snapshot
Operations
Produtos e/ou serviços de Abcellera Biologics Inc
- Development of a monoclonal antibody therapy for COVID-19 in collaboration with Eli Lilly, providing a significant tool in combating the pandemic.
- Partnerships with major pharmaceutical companies for antibody discovery utilizing their proprietary technology, expanding therapeutic options across various diseases.
- Creation of a deep learning-powered drug discovery platform that accelerates the identification of antibody candidates, enhancing the speed and efficiency of preclinical drug development.
- Offering an end-to-end solution for antibody discovery, including target validation, screening, and preclinical development, supporting partners through the drug development process.
- Collaboration with the Bill & Melinda Gates Foundation to identify antibody therapies for malaria and tuberculosis, aiming to address global health challenges.
- Development of a proprietary microfluidics technology for single B cell screening, enabling the rapid and efficient discovery of high-quality antibodies against challenging targets.
equipe executiva do Abcellera Biologics Inc
- Dr. Carl L.G. Hansen Ph.D.CEO, President & Chairperson
- Mr. Andrew Booth M.B.A.Chief Financial Officer
- Dr. Veronique Lecault Ph.D.CTO & Director
- Mr. Tryn T. Stimart Esq., J.D., M.Sc.Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
- Mr. Andrew Knowles M.Sc.VP of Operations
- Marcie Thiessen CPA, CGASenior Director of Finance & Accounting
- Mr. Martin Hogan M.Sc.Senior Director of Strategic Finance & IR
- Ms. Tiffany Chiu B.Sc., Ph.D.Vice President of Communications
- Graham Craig M.Sc.Director of Corporate Development
- Caitlin Webster CIPD, M.Sc.Director of Talent Development